Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
Author(s): Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, Walsh TJ, Ibrahim AS
Affiliation(s): Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson St., Torrance, CA 90502, USA. bspellberg@labiomed.org
Publication date & source: 2009-07, Antimicrob Agents Chemother., 53(7):3122-5. Epub 2009 May 11.
Publication type: Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.
|